Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:15 PM
Ignite Modification Date:
2025-12-24 @ 9:15 PM
NCT ID:
NCT04621604
Eligibility Criteria:
Inclusion Criteria:
* Patient at least 18 years of age
* Patient for whom anti-PD-1 antibody therapy (nivolumab or pembrolizumab) is given as monotherapy for relapsed or refractory classical Hodgkin's lymphoma within the scope of the WMA.
* Patient for whom a PET-CT for the evaluation of TMTV is available within 30 days prior to the first treatment without intercurrent antitumour therapy between the last PET-CT and the start of anti-PD1 treatment.
* For women of childbearing age, use of effective contraception
* Patient with free, informed and written consent
* Patient affiliated to a social security scheme
Exclusion Criteria:
* Persons of full age subject to legal protection (judicial protection, guardianship, trusteeship), persons deprived of their liberty, pregnant or breastfeeding women, persons unable to give consent
* Patient with a contraindication to NIV or PEM treatment
* Patient previously treated with anti-PD1 regardless of indication
* Patient treated with anti-PD1 in combination with other anti-tumour treatment
* Patient participating in another interventional clinical study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04621604
Study Brief:
Protocol Section:
NCT04621604